Loading stock data…
$92.08-0.09 (-0.10%)
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
Zimmer Biomet Holdings, Inc. in the Healthcare sector is trading at $92.08 with a market capitalization of $18.7B. Wall Street consensus targets $106.82 (22 analysts), implying a +16.0% move over the next 12 months. The stock is currently 14% below its 52-week high of $106.88, remaining 1.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.18B↑ | $2.09B↓ | $2.24B↑ | $2.00B↓ | $2.08B |
| Gross Profit | $1.54B↑ | $1.51B↑ | $1.45B↑ | $1.44B↓ | $1.49B |
| Operating Income | $374.00M↓ | $395.10M↑ | $282.60M↓ | $338.30M↓ | $396.40M |
| Net Income | $198.30M↓ | $238.10M↑ | $139.30M↓ | $230.90M↑ | $152.80M |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, inclu...
Academic risk and quality models computed from ZBH's own filings and price history, not from analyst opinion.
Mixed: 5 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z in the 1.81 to 2.99 grey zone, the band where the model gives no clear bankruptcy verdict.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, below the current 39.1% reading.
Fama-French 5-factor market beta. The five factors explain 12% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-13.